US20230003625A1 - Agent for cryopreservation and method for cryopreservation of mitochondria using the same - Google Patents

Agent for cryopreservation and method for cryopreservation of mitochondria using the same Download PDF

Info

Publication number
US20230003625A1
US20230003625A1 US17/897,011 US202217897011A US2023003625A1 US 20230003625 A1 US20230003625 A1 US 20230003625A1 US 202217897011 A US202217897011 A US 202217897011A US 2023003625 A1 US2023003625 A1 US 2023003625A1
Authority
US
United States
Prior art keywords
cryopreservation
mitochondria
agent
container
hepes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
US17/897,011
Other languages
English (en)
Inventor
Chi-Tang TU
Szu-Ting LIU
Li-Hsin YAO
Han-Chung CHENG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taiwan Mitochondrion Application Technology Co Ltd
Original Assignee
Taiwan Mitochondrion Application Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiwan Mitochondrion Application Technology Co Ltd filed Critical Taiwan Mitochondrion Application Technology Co Ltd
Assigned to TAIWAN MITOCHONDRION APPLIED TECHNOLOGY CO., LTD. reassignment TAIWAN MITOCHONDRION APPLIED TECHNOLOGY CO., LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CHENG, HAN-CHUNG, LIU, SZU-TING, TU, Chi-Tang, YAO, LI-HSIN
Publication of US20230003625A1 publication Critical patent/US20230003625A1/en
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00—Sampling; Preparing specimens for investigation
    • G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G01N1/42—Low-temperature sample treatment, e.g. cryofixation
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/02—Preservation of living parts
    • A01N1/0205—Chemical aspects
    • A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
    • A01N1/0221—Freeze-process protecting agents, i.e. substances protecting cells from effects of the physical process, e.g. cryoprotectants, osmolarity regulators like oncotic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues

Definitions

  • the present disclosure is related to an agent and a method for cryopreservation, more particularly to an agent and a method for cryopreservation of mitochondria.
  • Mitochondria are places where oxidative phosphorylation (OXPHOS) and adenosine triphosphate (ATP) synthesis occur. Since ATP is used as a source of energy in a cell, the mitochondria are described as the powerhouse of the cell. In addition to generate energy required by the cell, the mitochondria also participate in cell division, cell signaling and apoptosis of the cell, and the mitochondria has the ability to control the cell-division cycle. Since mitochondria are quite important organelles in the human body, problems with their function fail may result in diseases such as mitochondrial encephalomyopathy, and the neurodegenerative disease such as Parkinson's disease.
  • mitochondrial transplantation is one of the therapies.
  • the healthy mitochondria can be transplanted into cells to replace the damaged mitochondria when mitochondrial diseases are found, thereby relieving the symptoms of mitochondrial diseases.
  • cryoprotectants for cells have been developed, these cryoprotectants are not suitable for the cryopreservation of mitochondria. As to the cryopreservation of mitochondria by using conventional cryoprotectants for cells, mitochondria often become swollen or even broken, resulting in the inability of mitochondria to function properly after thawing. The prevention of damage to mitochondria during cryopreservation has become an important issue, so that there is a demand of cryoprotectants specialized to the cryopreservation of mitochondria.
  • an agent for cryopreservation includes trehalose, HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) and serum albumin (SA).
  • the agent for cryopreservation does not include potassium chloride (KCl), sodium chloride (NaCl), ethylene glycol, ethylene glycol tetraacetic acid (EGTA) and ethylenediaminetetraacetic acid (EDTA).
  • an agent for cryopreservation consists of trehalose, HEPES and SA.
  • a method for cryopreservation of mitochondria includes: providing the aforementioned agent for cryopreservation into a container; cooling down the agent for cryopreservation and the mitochondria in the container;
  • FIG. 1 is a flow chart illustrating a method for cryopreservation of mitochondria according to one embodiment of the present disclosure
  • FIG. 2 is a SEM image showing thawed mitochondria after 3 months cryopreservation by using a cryoprotectant according to one embodiment of the present disclosure
  • FIG. 3 is a SEM image showing thawed mitochondria after 3 months cryopreservation by using a cryoprotectant according to a first comparative example
  • FIG. 4 is a SEM image showing thawed mitochondria after 3 months cryopreservation by using a cryoprotectant according to a second comparative example
  • FIG. 5 is a graph showing oxygen consumption of thawed mitochondria after 1 month cryopreservation by using cryoprotectants according to one embodiment of the present disclosure and comparative examples.
  • FIG. 6 is a graph showing oxygen consumption of thawed mitochondria after 3 months cryopreservation by using cryoprotectants according to one embodiment of the present disclosure and comparative examples.
  • an agent for cryopreservation includes trehalose with a molar concentration of 150 mM to 300 mM, HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) with a molar concentration of 10 mM to 20 mM, and serum albumin (SA) with a mass percentage concentration of 0.1% to 1%.
  • the agent for cryopreservation does not include potassium chloride (KCl), ethylene glycol, ethylene glycol tetraacetic acid (EGTA) and ethylenediaminetetraacetic acid (EDTA).
  • an agent for cryopreservation may include trehalose, HEPES and SA, wherein a molar concentration of the trehalose in the agent is from 150 mM to 300 mM, a molar concentration of the HEPES in the agent is from 10 mM to 20 mM, and a mass percentage concentration of the SA in the agent is from 0.1% to 1%; and the agent for cryopreservation may not include KCl, ethylene glycol, EGTA and EDTA.
  • the agent for cryopreservation can be used for preparation of a cryoprotectant for cryopreservation of mitochondria, such as a cryoprotectant for cryopreservation of mitochondria obtained from mammal cells.
  • the mammal cells for example, are human cells.
  • the agent for cryopreservation does not include sodium chloride NaCl, KCl, ethylene glycol, EGTA and EDTA.
  • the trehalose in the agent can protect mitochondrial membrane to main integrity of a mitochondrion and normal function of the mitochondrial membrane.
  • the HEPES in the agent can keep pH of the cryoprotectant at a nearly constant value, and HEPES can also make the cryoprotectant as an isotonic solution for mitochondria.
  • the SA in the agent can keep constant osmotic pressure of the cryoprotectant and that of the mitochondria.
  • the SA may be derived from an individual which is the same species as one in which the mitochondria are designated to be cryopreserved; for example, human serum albumin (HSA) is selected for the cryopreservation of human mitochondria, and dog serum albumin (DSA) is selected for the cryopreservation of canine mitochondria.
  • HSA human serum albumin
  • DSA dog serum albumin
  • the SA may be derived from an individual which belongs different species from one in which the mitochondria are designated to be cryopreserved.
  • KCl therein is provided for adjusting the cryoprotectant to be a buffer solution and isotonic solution for mitochondria.
  • EGTA and EDTA in the conventional cryoprotectant can capture calcium ions which are generated when cell are damaged so as to prevent a large amount of calcium ions from entering the mitochondria to thereby cause changes in mitochondrial membrane permeability which may result in mitochondrial swelling or even lysis.
  • cryoprotectant according to the present disclosure does not include KCl, ethylene glycol, EGTA and EDTA.
  • the mitochondria cryopreserved by using the cryoprotectant of the present disclosure can enjoy better integrity and ATP synthesis ability. Therefore, the cryopreserved mitochondria maintain better function after they are thawed, which in turn leads to better performance in subsequent usage.
  • an agent for cryopreservation consists of trehalose with a molar concentration of 150 mM to 300 mM, HEPES with a molar concentration of 10 mM to 20 mM, and SA with a mass percentage concentration of 0.1% to 1%.
  • an agent for cryopreservation according to one embodiment of the present disclosure may consist of trehalose, HEPES and SA, wherein a molar concentration of the trehalose in the agent is from 150 mM to 300 mM, a molar concentration of the HEPES in the agent is from 10 mM to 20 mM, and a mass percentage concentration of the SA in the agent is from 0.1% to 1%.
  • the molar concentration of the trehalose is from 150 mM to 300 mM, preferably 200 mM to 300 mM, more preferably 250mM to300 mM.
  • the molar concentration of the HEPES is from 10mM to 20 mM, preferably 10 mM to 16 mM, more preferably 10 mM to13 mM.
  • the mass percentage concentration of the SA is from 0.1% to 1%, preferably 0.1% to 0.7%, more preferably 0.1% to 0.3%.
  • a ratio of the molar concentration of the trehalose to that of the HEPES may be from 13 to 17, preferably 14 to 16, more preferably 15.
  • the agent for cryopreservation is aqueous and can be used directly, and the solvent used herein may be deionized water, but the present disclosure is not limited thereto.
  • the agent for cryopreservation is solid, and the solid agent should be firstly prepared into liquid form with pure water (e.g., deionized water) or other solvent acceptable to the cell to be ready for use.
  • a weight ratio among dried trehalose, dried HEPES and dried serum albumin may be represented by X:Y:Z, in which X is from 92.42 to 112.96, Y is from 2.14 to 2.62, and Z is from 0.9 to 1.1; preferably, X:Y:Z is 102.69:2.38:1.
  • FIG. 1 showing a flow chart illustrating a method for cryopreservation of mitochondria according to one embodiment of the present disclosure.
  • a method for cryopreservation of mitochondria may be applied to the cryopreservation of mitochondria obtained from mammal cells, such as human cells, and the method may include the following steps.
  • a first step S 101 the container is precooled.
  • the container may be placed in liquid nitrogen for precooling for 20 seconds to 40 seconds.
  • the container may be test tube, centrifuge tube or vial.
  • a second step S 102 the agent (or cryoprotectant) and mitochondria are provided in the container.
  • the precooled container is rewarmed at room temperature for 5 seconds to 15 seconds, and then the aforementioned agent of the present disclosure as well as the mitochondria are placed into the bottom of the container.
  • the agent and the mitochondria have been placed in the container, an operator can tap the container to aggregate the agent and the mitochondria to the bottom of the container, which prevents mitochondria residues on the inner wall of the container.
  • the mitochondria residues on the inner wall of the container may be not rinsed with the agent for cryopreservation, so that these residual mitochondria easily swell or break during cryopreservation because they are not protected by the agent.
  • a third step S 103 the agent and the mitochondria accommodated in the container is cooled down.
  • the container accommodating the agent and the mitochondria may be placed in liquid nitrogen for 5 seconds to 15 seconds for cooling, and the agent and the mitochondria in the container are in a frozen state after cooling.
  • a fourth step S 104 the container accommodating the agent and the mitochondria is taken from the liquid nitrogen, and the agent for cryopreservation and the mitochondria in the container, which have been cooled down, are preserved.
  • the container accommodating the agent and the mitochondria may be taken from the liquid nitrogen, and the container as well as the cooled agent and mitochondria accommodated therein may be placed in a refrigerator for cryopreservation at a temperature of ⁇ 70° C. to ⁇ 90° C.
  • the container containing the agent and frozen mitochondria is taken from the refrigerator, and is thawed by gently shaking for 45 seconds to 65 seconds in warm water at 25° C. to 35° C. After the agent and the mitochondria in the container are completely thawed, the container with the agent and the mitochondria are inserted into crushed ice pool to keep the mitochondria at 4° C. to 10° C. for subsequent usage.
  • An example of said subsequent usage is the use of mitochondria for mitochondrial transplantation to treat mitochondrial-related diseases.
  • the thawed mitochondria even though they were cryopreserved, can enjoy better integrity and ATP synthesis ability. Therefore, the cryopreserved mitochondria maintain better function after they are thawed, which in turn leads to better performance in subsequent usage.
  • the stem cells can be prepared in a flask with a medium including 10 wt% fetal bovine serum (FBS) and cultured for 168 hours to be ready for use.
  • the stem cells may be embryonic stem cells, induced stem cells, amniotic mesenchymal stem cells, placental mesenchymal stem cells, chorionic mesenchymal stem cells, umbilical cord mesenchymal stem cells, adipose derived stem cells (ADSC), bone marrow mesenchymal stem cells, or other sources of adult stem cells.
  • FBS fetal bovine serum
  • the stem cells may be embryonic stem cells, induced stem cells, amniotic mesenchymal stem cells, placental mesenchymal stem cells, chorionic mesenchymal stem cells, umbilical cord mesenchymal stem cells, adipose derived stem cells (ADSC), bone marrow mesenchymal stem cells, or other sources of adult stem cells.
  • the mitochondria used in the experiment are prepared as follows. Firstly, about a mount of 10 8 to 10 9 ADSCs are taken from the cell-culture dish. Next, the ADSCs are loaded into test tube with mitochondria isolation buffer (Ibc: 225 mM mannitol, 75 mM sucrose, 30 mM Tris-HCl, pH 7.4), and the ADSCs are homogenized with the buffer by using gentleMACSTM dissociator. The broken ADSCs are placed in Percoll at a volume percentage of 30%, and the precipitate is removed by ultra-high speed centrifugation at 95,000g for 30 minutes (min), followed by high speed centrifugation at 13,000g for 10 min to isolate precipitated mitochondria. Then, the isolated mitochondria were rinsed with mitochondrial protein separation buffer for subsequent experiments.
  • mitochondria isolation buffer Ibc: 225 mM mannitol, 75 mM sucrose, 30 mM Tris-HCl, pH 7.4
  • the broken ADSCs are placed in Percoll at a volume percentage of 30%
  • the cryopreservation of the mitochondria is described as follows. Firstly, centrifuge tubes are pre-cooled in liquid nitrogen for 30 seconds. Next, the centrifuge tube are taken from the liquid nitrogen and rewarmed at room temperature for 10 seconds. Next, 300 micrograms ( ⁇ g) of mitochondria which have been isolated from stem cells and 60 microliters ( ⁇ L) of agent (or cryoprotectant) are placed into the space at the bottom of the centrifuge tube. Next, each tube is slightly tapped to ensure that the mitochondria and the agent are aggregated at the bottom of the tube. Next, the centrifuge tubes containing the mitochondria and the agent are placed in liquid nitrogen and allowed to stand for 10 seconds to bring the mitochondria and agent into a frozen state. Finally, the centrifuge tubes with frozen mitochondria and agent are placed in a refrigerator with an internal temperature of ⁇ 80° C. for cryopreservation.
  • the aforementioned agent or cryoprotectant used in the method for cryopreservation of mitochondria may be selected from an embodiment of the present disclosure, a comparative example 1 or a comparative example 2.
  • the compositions of the agents of an embodiment of the present disclosure (EM), a comparative example 1 (CE1) and a comparative example 2 (CE2) are listed in Table I.
  • the method for thawing cryopreserved mitochondria is described as follows. Firstly, the centrifuge tubes containing cryopreserved mitochondria and the agent are taken from the refrigerator, and the centrifuge tubes containing cryopreserved mitochondria and the agent are immediately rinsed with warmed water bath at 30° C. The centrifuge tubes are gently shaken for 55 seconds during the warm water bath. After the mitochondria and the agent in the centrifuge tubes are completely thawed, the centrifuge tubes are placed into crushed ice pool for subsequent usage.
  • thawed mitochondria that have been cryopreserved for 3 months by using the agent selected from EM, CE1 or CE2 is evaluated by SEM.
  • the thawed mitochondria are taken from the centrifuge tubes, rinsed with PBS (Phosphate buffered saline), and then made into specimens for SEM.
  • PBS Phosphate buffered saline
  • FIG. 2 is a SEM image showing thawed mitochondria after 3 months cryopreservation by using an agent/cryoprotectant according to one embodiment of the present disclosure.
  • FIG. 3 is a SEM image showing thawed mitochondria after 3 months cryopreservation by using an agent/cryoprotectant according to a first comparative example.
  • FIG. 4 is a SEM image showing thawed mitochondria after 3 months cryopreservation by using an agent/cryoprotectant according to a second comparative example.
  • FIG. 2 It can be observed that a large amount of undamaged mitochondria is presented in FIG. 2 , accompanied with small average diameter of the undamaged mitochondria and sharp (clear) cristae (Mitochondrial cristae) of the inner mitochondrial membrane. In contrast, a small amount of undamaged mitochondria and large average diameter of the undamaged mitochondria can be observed in FIG. 3 . A very small amount of undamaged mitochondria and very large average diameter of the undamaged mitochondria can be observed in FIG. 4 . Thus, as can be seen from FIG. 2 through FIG.
  • the agent of the embodiments of the present disclosure does not include KCl, EGTA or EDTA
  • the mitochondria cryopreserved by using the agent of the present disclosure keep good integrity after thawing and do not suffer high average diameter as well as poor integrity due to the lack of KCl, EGTA or EDTA.
  • the ATP synthesis ability of the thawed mitochondria after 1 month and 3 months cryopreservation by using the agent selected from EM, CE1 or CE2 is measured by a
  • the Seahorse XF analyzer The thawed mitochondria are taken from the centrifuge tubes, rinsed with PBS, and then assayed with the Seahorse XF analyzer.
  • the Seahorse XF analyzer measures ATP synthesis ability of the thawed mitochondria by the following steps: 20 ⁇ g of mitochondria are placed in the analytical wells with analytical medium, and then the basal oxygen consumption rate in the mitochondria is detected. Then, some amount of ADP is added into the wells as the material for ATP synthesis, and the ATP synthesis oxygen consumption rate in the mitochondria is detected at this time. Then, some ATP synthesis inhibitors are added to decrease the activity of the mitochondria to synthesize ATP, and non-ATP synthesis oxygen consumption rate in the mitochondria is detected at this time.
  • the ATP synthesis inhibitors may be oligomycin.
  • an appropriate concentration of anti-coupler is added to the wells, and the mitochondria are allowed to idle in the limiting condition without disrupting the electron transport chain of the inner mitochondrial membrane to assess oxygen consumption rate of the electron transport chain of the inner mitochondrial membrane.
  • the anti-coupler may be carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone (FCCP).
  • FCCP carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone
  • electron transport chain inhibitors are added into the wells to completely stop mitochondrial oxygen consumption, thereby determining background value of the oxygen consumption rate.
  • the electron transport chain inhibitors may be rotenone, antimycin A or a combination thereof.
  • FIG. 5 is a graph showing oxygen consumption of thawed mitochondria after 1 month cryopreservation by using agents/cryoprotectants according to one embodiment of the present disclosure and comparative examples.
  • FIG. 6 is a graph showing oxygen consumption of thawed mitochondria after 3 months cryopreservation by using agents/cryoprotectants according to one embodiment of the present disclosure and comparative examples.
  • the thawed mitochondria which were cryopreserved by using the agent of EM, have significantly higher oxygen consumption rate, higher ATP synthesis oxygen consumption rate and higher electron transport chain oxygen consumption rate that that cryopreserved by using the agents of CE1 and CE2. It can be concluded that the mitochondria cryopreserved for 1 month by using the agent of EM have better health and normal function after thawing. As shown in TABLE II and FIG.
  • the thawed mitochondria which were cryopreserved by using the agent of EM, have significantly higher oxygen consumption rate, higher ATP synthesis oxygen consumption rate and higher electron transport chain oxygen consumption rate that that cryopreserved by using the agents of CE1 and CE2. It can be concluded that the mitochondria cryopreserved for 3 months by using the agent of EM have better health and normal function after thawing.
  • the thawed mitochondria which were cryopreserved by using the agent/cryoprotectant according to the present disclosure, enjoy better ATP synthesis ability. Accordingly, the thawed mitochondria, which were cryopreserved by using the agent/cryoprotectant according to the present disclosure, have a potential to be applied for (that is, more suitable) mitochondrial transplantation therapy.
  • the mitochondria cryopreserved by using the agent/cryoprotectant and method of the present disclosure can enjoy better integrity and ATP synthesis ability. Therefore, the cryopreserved mitochondria maintain better function after they are thawed, which in turn leads to better performance in subsequent usage.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Dentistry (AREA)
  • Environmental Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
US17/897,011 2020-02-28 2022-08-26 Agent for cryopreservation and method for cryopreservation of mitochondria using the same Pending US20230003625A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2020/077063 WO2021168764A1 (fr) 2020-02-28 2020-02-28 Agent de cryoconservation et procédé de cryoconservation de mitochondrie utilisant celui-ci

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2020/077063 Continuation-In-Part WO2021168764A1 (fr) 2020-02-28 2020-02-28 Agent de cryoconservation et procédé de cryoconservation de mitochondrie utilisant celui-ci

Publications (1)

Publication Number Publication Date
US20230003625A1 true US20230003625A1 (en) 2023-01-05

Family

ID=77489775

Family Applications (1)

Application Number Title Priority Date Filing Date
US17/897,011 Pending US20230003625A1 (en) 2020-02-28 2022-08-26 Agent for cryopreservation and method for cryopreservation of mitochondria using the same

Country Status (3)

Country Link
US (1) US20230003625A1 (fr)
CN (1) CN115023135B (fr)
WO (1) WO2021168764A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023191495A1 (fr) * 2022-03-29 2023-10-05 주식회사 파이안바이오테크놀로지 Mitochondries congelées et lyophilisées et leur utilisation
WO2023237789A1 (fr) 2022-06-10 2023-12-14 Cellvie Ag Composition et procédé de cryoconservation de mitochondries

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040185524A1 (en) * 2000-02-10 2004-09-23 Crowe John H. Biological samples and method for increasing survival of biological samples
TW202309276A (zh) * 2016-08-03 2023-03-01 美商武田疫苗股份有限公司 用於與經改良之調配物一起穩定黃病毒的組成物及方法
WO2018110159A1 (fr) * 2016-12-14 2018-06-21 株式会社大塚製薬工場 Liquide de cryoconservation de cellules de mammifère
CN108739796A (zh) * 2018-06-05 2018-11-06 瑞柏生物（中国）股份有限公司 一种玻璃化冷冻液及其制备方法
TWI766137B (zh) * 2018-12-24 2022-06-01 台灣粒線體應用技術股份有限公司 冷凍保存劑與使用其的粒線體冷凍保存方法
CN110684817B (zh) * 2019-10-23 2021-07-20 北京赛科希德科技股份有限公司 人纤维蛋白体外降解方法

Also Published As

Publication number Publication date
WO2021168764A1 (fr) 2021-09-02
CN115023135A (zh) 2022-09-06
CN115023135B (zh) 2024-04-19

Similar Documents

Publication Publication Date Title
US20230003625A1 (en) Agent for cryopreservation and method for cryopreservation of mitochondria using the same
Yeste State-of-the-art of boar sperm preservation in liquid and frozen state
De Leeuw et al. Cold-induced ultrastructural changes in bull and boar sperm plasma membranes
Gao et al. Fundamental cryobiology of mammalian spermatozoa
Tapia et al. The membrane of the mammalian spermatozoa: much more than an inert envelope
JP6879949B2 (ja) 治療目的のための細胞の凍結保存方法
Stanic et al. Effect of pentoxifylline on motility and membrane integrity of cryopreserved human spermatozoa
Farshad et al. The cryoprotective effects of amino acids supplementation on cooled and post-thaw Markhoz bucks semen quality
Grasa et al. Ram sperm selection by a dextran/swim‐up procedure increases fertilization rates following intrauterine insemination in superovulated ewes
Iqbal et al. Cryoprotectant effect of trehalose in extender on post‐thaw quality and in vivo fertility of water buffalo (Bubalus bubalis) bull spermatozoa
Tomás et al. Addition of cholesterol‐loaded cyclodextrins to the thawing extender: Effects on boar sperm quality
EL-RAEY et al. Effect of melatonin on buffalo bull sperm freezability, ultrastructure changes and fertilizing potentials
WO2022241417A1 (fr) Méthodes et compositions pour prolonger la conservation d'un organe et d'un tissu
Gomes-Alves et al. Use of commercial extenders and alternatives to prevent sperm agglutination for cryopreservation of brown bear semen
TWI766137B (zh) 冷凍保存劑與使用其的粒線體冷凍保存方法
Oh et al. Effect of adding taurine, hypotaurine and trehalose as antioxidants to a tris-based egg yolk extender on Korean Jeju black bull sperm quality following cryopreservation
TWI836467B (zh) 冷凍保存劑及其用途
Yi et al. Lactose-egg yolk diluent supplemented with N-acetyl-D-glucosamine affect acrosome morphology and motility of frozen-thawed boar sperm
Goericke-Pesch et al. Effect of seminal plasma vesicular structures in canine frozen-thawed semen
Dalal et al. Comparison of three programmable freezing protocols for the cryopreservation of buffalo bull semen
Bos‐Mikich et al. Analysis of the chromosome complement of frozen‐thawed mouse oocytes after parthenogenetic activation
Vickram et al. Effects of various semen extenders on semen parameters for the purpose of human male fertility preservation
Le Minh et al. Uncoupling protein-2 deficiency provides protection in a murine model of endotoxemic acute liver failure
Liu et al. Trehalose inhibited the phagocytosis of refrigerated platelets in vitro via preventing apoptosis
Anand et al. Effect of dilution and sperm concentration on post thaw semen quality in Barbari buck

Legal Events

Date Code Title Description
AS Assignment

Owner name: TAIWAN MITOCHONDRION APPLIED TECHNOLOGY CO., LTD., TAIWAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:TU, CHI-TANG;LIU, SZU-TING;YAO, LI-HSIN;AND OTHERS;REEL/FRAME:060943/0822

Effective date: 20220823

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION